NCX 470 met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline compared to the ...

New presbyopia-correcting eye drops, including VIZZ and Qlosi, offer alternatives to Vuity, with more options under FDA ...

Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by ...

VivaVision Biotech welcomes renowned ophthalmologist Quan Dong Nguyen to its scientific advisory board with hopes of boosting ...

Cyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

The company previously provided an update in April 2025 stating its intention to lay off approximately 65% of the company ...

RAMQ is a public organization introduced in 1970, following the adoption of the universal health care system in Canada.

Annexin Pharmaceuticals initiates a Phase 2a study for ANXV in diabetic retinopathy to explore new treatment options and ...

Dan Ignaszewski explains how the national advocacy campaign aims to unite patients, researchers, and clinicians to protect ...

The two aim to develop a potential first-in-class melanocortin receptor-targeted treatment for patients with retinal diseases ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...